|4Oct 16, 4:07 PM ET

Kelsey Stephen Michael 4

4 · Revolution Medicines, Inc. · Filed Oct 16, 2024

Insider Transaction Report

Form 4
Period: 2024-10-14
Transactions
  • Exercise/Conversion

    Common Stock

    2024-10-14$4.09/sh+16,666$68,164281,074 total
  • Sale

    Common Stock

    2024-10-14$50.08/sh2,610$130,702264,408 total
  • Sale

    Common Stock

    2024-10-14$49.38/sh14,056$694,102267,018 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-10-1416,66623,332 total
    Exercise: $4.09From: 2023-03-13Exp: 2029-03-12Common Stock (16,666 underlying)
Footnotes (4)
  • [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.
  • [F2]Includes 86,400 restricted stock units.
  • [F3]The transaction was executed in multiple trades in prices ranging from $48.95 to $49.94, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F4]The transaction was executed in multiple trades in prices ranging from $49.95 to $50.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Documents

1 file
  • 4
    form4.xmlPrimary